GeneFerm Biotechnology Co

GeneFerm Biotechnology Co EPS

The Earnings per Share (EPS) of GeneFerm Biotechnology Co (1796.TWO) as of Nov 3, 2026 is 0.70 TWD. In the previous year, Earnings per Share (EPS) was -0.54 TWD — a change of -228.12% (higher).

EPS

0.70TWD

YoY

-228.12%

Last updated:

Earnings per Share (EPS) of GeneFerm Biotechnology Co is 2025 0.70 TWD. Earnings per Share (EPS) of GeneFerm Biotechnology Co was 2024 -0.54 TWD. It decreases by -228.12% higher compared to the previous year.

The GeneFerm Biotechnology Co EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2018
0.25 TWD
Jan 1, 2019
-0.66 TWD
Jan 1, 2020
0.16 TWD
Jan 1, 2021
1.41 TWD
Jan 1, 2022
2.25 TWD
Jan 1, 2023
2.98 TWD
Jan 1, 2024
-0.54 TWD
Jan 1, 2025
0.70 TWD
The GeneFerm Biotechnology Co EPS history
YEAREPSYoY
0.70TWD-228.12%
-0.54TWD-118.26%
2.98TWD+32.05%
2.25TWD+60.14%
1.41TWD+766.88%
0.16TWD-124.44%
-0.66TWD-367.09%
0.25TWD-63.46%
0.68TWD-81.65%
3.71TWD+64.35%
2.26TWD-393.78%
-0.77TWD-413.04%
0.25TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneFerm Biotechnology Co Stock analysis

What does GeneFerm Biotechnology Co do? GeneFerm Biotechnology Co., Ltd. generates revenue through the manufacture and sale of health food and supplement products, including fermented products, medicinal mushrooms, lactic acid bacteria products, and fruit and vegetable fermented concentrate products. The company also offers related manufacturing services, health food design, and research and development services. Its primary customers are consumers seeking health-focused dietary supplements, with a focus on fermented and natural health food solutions. The firm targets health-conscious individuals and wellness-oriented markets through its product portfolio. The business model relies on direct sales of its branded health food products, leveraging the growing demand for natural and fermented dietary supplements. The company's R&D services support product innovation, while manufacturing services cater to partners requiring specialized production capabilities. Health food design services further enhance its offerings for clients in the wellness industry. GeneFerm's revenue streams are derived from both product sales and service-based offerings, with a strong emphasis on fermented health food solutions. The company's focus on medicinal mushrooms and lactic acid bacteria products differentiates its market position, appealing to consumers interested in natural health remedies and probiotic benefits. GeneFerm Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneFerm Biotechnology Co stock

Earnings per Share (EPS) of GeneFerm Biotechnology Co is 0.70 TWD in 2025.

Earnings per Share (EPS) of GeneFerm Biotechnology Co changed from -0.54 TWD to 0.70 TWD, representing a -228.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) GeneFerm Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — GeneFerm Biotechnology Co

All Key Metrics — GeneFerm Biotechnology Co